-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
T9ycfcjFLcqEET9Gzk78qiyG6MUsMKoLZir14L2WU7Jv9TtGlZoqvZXSC03gOjyS
KLvNZITAjqV3llyYhz21/g==
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 10-Q (Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2001 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission file number: 0-22788
Axys Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
180 Kimball Way
(650) 829-1000
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file reports), and (2) has been subject to such filing
requirements for the past 90 days. YES [X] NO [ ],
The number of outstanding shares of the registrant's Common Stock, $0.001
par value, was 37,528,412 as of April 30, 2001.
Axys Pharmaceuticals, Inc. ________________
* The financial information contained herein should be read in conjunction with
the consolidated financial statements and notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 2000,
filed with the Securities and Exchange Commission on March 30, 2001.
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AXYS PHARMACEUTICALS, INC.
__________________
(1) The balance sheet at December 31, 2000 has been derived from the audited
financial statement at that date but does not include all of the information
and footnotes required by generally accepted accounting principles for
complete financial statements.
See accompanying notes.
AXYS PHARMACEUTICALS, INC.
See accompanying notes.
AXYS PHARMACEUTICALS, INC.
See accompanying notes.
AXYS PHARMACEUTICALS, INC.
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited financial statements included herein have been
prepared by Axys Pharmaceuticals, Inc. ("Axys" or the "Company") according to
the rules and regulations of the Securities and Exchange Commission. Certain
information and footnote disclosures normally included in complete financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted pursuant to such rules and regulations. The
financial statements reflect, in the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to state fairly the
financial position and results of operations as of and for the periods
indicated. The results of operations for the three months ended March 31, 2001
are not necessarily indicative of the results to be expected for subsequent
quarters or the full fiscal year. On April 28, and December 22, 2000, respectively, the Company completed the
sale of two of its subsidiaries: its combinatorial chemistry business, Axys
Advanced Technologies, Inc. ("AAT"), to Discovery Partners International, Inc.
(Nasdaq: DPII "DPI") and its pharmacogenomics subsidiary PPGx, Inc. to DNA
Sciences, Inc. The Company reclassified operating results previously reported
for the three months ended March 31, 2000 to reflect the results of these
subsidiaries as discontinued operations, in accordance with Accounting
Principles Board Opinion No. 30 (APB 30). These financial statements should be read in conjunction with
the audited financial statements and the notes thereto included in the Company's
2000 Annual Report on Form 10-K filed with the Securities and Exchange
Commission. Reclassifications Certain prior period amounts have been reclassified to conform to the March
31, 2001 presentations. Uses of Estimates The preparation of financial statements in conformity
with accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the amounts reported in
the financial statements and accompanying notes. Actual results could differ
from those estimates, and such differences could be material. Changes in Accounting Principle In June 1998, the Financial Accounting Standards Board issued
Statement No. 133, Accounting for Derivative Instruments and Hedging
Activities (FAS 133), which is required to be adopted in years beginning
after June 15, 2000. The Statement requires the recognition of all derivative
instruments on the balance sheet to be recorded at fair market value. The
accounting for changes in the fair value (i.e., gains or losses) of a derivative
instrument depends on whether it has been designated and qualifies as part of a
hedging relationship and further, on the type of hedging relationship. We have
not designated our derivative instruments as hedges, therefore, all changes in
the fair value of our derivative instruments are recorded in earnings. The
adoption of FAS 133 at January 1, 2001 resulted in the cumulative effect of an
accounting change of $972,000 being recognized in the statement of
operations. Derivative Instruments At March 31, 2001, the Company had two derivative
instruments: (1) A warrant held in connection with the DPI investment; and (2) A
stock option plan covering a portion of the Company's investment in DPI, in
which the Company has granted certain employees options to acquire common stock
in this investment (See Note 2). During the first quarter of 2001 the Company
recorded a charge of $978,000 in connection with the warrant to reflect the
change in fair value and a credit of approximately $1.1 million in connection
with the stock option plan to reflect the changes in fair value of these derivative instruments. 2. Investment in Equity-Method Investee Investment in equity-method investee consists of the
Company's investment in DPI as a result of the merger agreement between DPI and
the Company for the sale of AAT in April 2000. The Company accounts for its
investment in DPI under the equity method of accounting. At March 31, 2001 the Company owned 7,425,000 shares of DPI
common stock, which represented approximately 31% ownership of the outstanding
shares of DPI. The Company adopted a Key Personnel Stock Option
Plan, whereby key personnel have been granted options to purchase shares of
stock in Axys' affiliated companies.
The participants in the plan have the right to purchase up to 5% of the
Company's equity holdings in the affiliated companies. As a result of this
plan, the financial statements reflect a credit of $1.1 million related to
the change in fair value associated with this plan. The market value of DPI stock held by Axys as of March 31,
2001 was approximately $47.3 million. Summarized statement of operations information of DPI for the
three month periods ended March 31, 2001 and 2000 was as follows: 3. Investment in Akkadix On March 15, 2001, two third party investors of
Akkadix Corporation exercised a contractual option extended to them by the
Company to exchange their approximately 2.7 million shares of Akkadix's Series A
preferred stock for approximately 2.5 million shares of the Company's common
stock. The fair market value of Axys common stock exchanged for Akkadix
preferred stock was approximately $9.0 million on the date of the option
exercise. The conversion of shares will result in an increase in the
Company's equity ownership of Akkadix from approximately 31% to 44% (as of March
31, 2001).
Changing conditions in private equity markets during the first quarter forced
Akkadix to sharply reduce their operations as the company was unable to secure
planned new equity funding. A substantial percentage of their employees were
terminated and Akkadix vacated their office/laboratory space. The Company has
concluded that the future viability of the Akkadix business is highly uncertain.
Accordingly, in conformance with the equity method of accounting, we incurred a
non-cash charge of $9.0 million during the first quarter of 2001, recognizing a permanent impairment in the
value of the Company's investment in Akkadix. The company does not anticipate
any future benefit from this investment. 4. Comprehensive Loss Comprehensive loss is comprised of net
loss and unrealized holding gains and losses on available-for-sale securities.
Components of comprehensive loss are as follows: ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS The following discussion
contains both historical information and forward-looking statements that involve
risks and uncertainties. Forward-looking statements include projections and
other statements about events that may occur at some point in the future. The
Company's actual results could differ significantly from those described in the
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed in this section as
well as under "Item 1. Business," including, "What Factors Could Cause Our
Results To Differ Significantly From Those You Might Expect" and "What Matters
Should Stockholders Consider with Respect to the Company?", in the Company's
Annual Report on Form 10-K for the year ended December 31, 2000 filed with the
Securities and Exchange Commission. Overview We are a biopharmaceutical company focused on the discovery,
design and development of therapeutic small molecules that address significant
markets with major unmet medical needs. We collaborate with large pharmaceutical
companies in discovering therapeutics for chronic diseases for which there are
large markets. We also selectively focus our own resources on discovering and
developing therapeutics for the treatment of various types of cancer and other
specialty market therapeutics. We have on-going programs in the treatment of
autoimmune, inflammatory diseases, and cancer. Our drug design platform
integrates advanced biology, chemistry, biophysics and information technologies
to optimize the potency, selectivity and physical properties of new drugs,
making the drug discovery process more efficient and productive. In February 2001, we received a research milestone
payment from Merck & Co. for meeting a pre-agreed milestone in the
development of a compound being studied for use in the treatment of
osteoporosis, a disease that affects an estimated 40 percent of women over the
age of 50. The compound selected by Merck is a potent and selective inhibitor of
Cathepsin K, a cysteine protease that has been demonstrated to play a key role
in bone resorption. In March 2001, we recorded revenue from a research
milestone from Aventis, for successfully completing a pivotal in vivo
proof-of-concept study which confirmed the mechanism of action for orally
administered inhibitors of Cathepsin S, another human cysteine protease. The
collaboration with Aventis is focused on development of Cathepsin S inhibitors
for potential applications in treating inflammation and autoimmune disease,
including rheumatoid arthritis, asthma, atherosclerosis, COPD and rhinitis. Also in March 2001, two investors in Akkadix Corporation
exercised an option, extended to them by Axys, to exchange their 2.7 million
shares of Series A Preferred Stock of Akkadix for approximately 2.5 million shares of
Axys common stock. The fair market value of Axys common stock exchanged for
Akkadix preferred stock was approximately $9.0 million. As a result of the
exercise of these options, Axys' ownership of Akkadix voting stock increased
from 31% to approximately 44%. During the first quarter of 2001, Akkadix sharply
reduced their operations because of diminished financial resources. A
substantial percentage of their employees were terminated and Akkadix vacated
their office/laboratory space. We have concluded that the future viability of
the Akkadix business is highly uncertain. Accordingly, in conformance with the
equity method of accounting, we incurred a non-cash charge of $9.0 million
during the quarter recognizing a permanent impairment in the value of our
investment in Akkadix. The company does not anticipate any future benefit from
this investment. To date, we have not generated any product revenue from our
drug discovery programs and we do not expect to generate product revenue for at
least several years. As of March 31, 2001, we had an accumulated deficit of $285
million. We expect that losses will fluctuate from quarter to quarter, that such
fluctuations may be substantial, and that results from prior quarters may not be
indicative of future operating results. Included in our accumulated deficit at
March 31, 2001 was approximately $147 million of acquired in-process research
and development from the acquisitions of Khepri Pharmaceuticals, Inc. in 1995
and Sequana Therapeutics, Inc. ("Sequana") in January 1998. We expect our
sources of revenue, if any, for the next several years to consist of payments
under corporate partnerships. The process of developing our products will
require significant additional research and development, preclinical testing and
clinical trials, as well as regulatory approval. These activities, together with
our general and administrative expenses are expected to result in significant
operating losses for the foreseeable future. We will not receive product
revenues or royalties from our collaborative partners before completing clinical
trials and successfully commercializing these products. We are subject to risks common to biopharmaceutical
companies, including risks inherent in our research and development efforts and
clinical trials, reliance on collaborative partners, enforcement of patent and
proprietary rights, the need for future capital, potential competition and
uncertainty of regulatory approvals. In order for a product to be
commercialized, it will be necessary for us, and in some cases, our
collaborators, to conduct preclinical tests and clinical trials to demonstrate
the efficacy and safety of our product candidates, obtain regulatory clearances
and enter into manufacturing, distribution and marketing arrangements as well as
obtain market acceptance. There can be no assurance that we will generate
revenues or achieve and sustain profitability in the future. Results of Operations Collaboration and Licensing Revenues Our collaboration and licensing revenues were $3.1
million for the three months ended March 31, 2001, compared to $1.4 million for
the same period in 2000. The increase was primarily due to milestones earned
from corporate collaborations with both Merck and Aventis. Research and Development Our research and development expenses were $8.9 million
for the three months ended March 31, 2001, compared to $7.9 million for the same
period in 2000. The overall increase for the first three months of 2001 was
primarily due to clinical development expenses incurred in connection with
clinical studies for APC 2059. General and Administrative Our general and administrative expenses were $3.2 million
for the three months ended March 31, 2001, compared to $2.8 million for the same
period in 2000. The increase was primarily due to upgrading our information
systems and network infrastructure. Non-cash compensation income We recorded non-cash compensation income of $1.1 million
for the three months ended March 31, 2001, relating to the adoption of FAS 133
in January 2001. We recorded a credit as a result of the decline in fair value
of the company's liability under the Key Stock Option Employee Plan. Under this
plan, certain employees of Axys have been granted contractual options to
purchase shares of our investment of Discovery Partners International, Inc.
(DPI). Interest Income and Interest Expense Interest income was $531,000 for the three months ended
March 31, 2001, compared to $141,000 for the same period in 2000. The increase
was primarily due to the increase in average cash investment balances during the
first quarter of 2001, compared to the first quarter of 2000. Interest expense
was $1,474,000 for the three months ended March 31, 2001, compared to $176,000
for the same period in 2000. The increase in the first quarter was primarily due
to the interest expense on the subordinated notes payable. Interest expense on
these notes consists of the 8% face value interest rate and the amortization of
debt issuance costs. Equity Interest in Loss of Equity-Method Investee We recorded a $9.1 million loss in connection with our
equity method investees during the three months ended March 31, 2001. These
losses reflect our pro rata share loss from our investments in DPI and the write
off of our remaining investment in Akkadix. Other Expense Other expense was $978,000 for the three months ended
March 31, 2001 and represents the change in fair value of the warrants received
as part of our investment in DPI in conformity with FAS 133 adopted in January
2001. Liquidity and Capital Resources We have financed our operations since inception primarily
through private and public offerings of capital stock, through corporate
collaborative research and from a secured convertible note. As of March 31,
2001, we have accumulated, approximately $229 million in net proceeds from
offerings of our capital stock. In addition, we have accumulated approximately
$183 million from our collaborative research agreements. Our principal sources of liquidity are our cash and
investments, which totaled $29.4 million on March 31, 2001. Included in our
investments on March 31, 2001 were 35,450 shares of
common stock., which are subject to a lock-up agreement that restricts our
ability to sell the securities. The lock up expires in June 2001. In 2000, we sold our Axys Advanced Technologies subsidiary to
DPI for approximately 7.4 million shares of DPI common stock. Later in 2000, we
sold our interest in PPGx to DNA Sciences, Inc. for approximately 1.5 million shares of Series
D Preferred Stock. We used cash and cash equivalents of $10.9 million in the
operations of our company during the first quarter of 2001 compared to $11.9
million in the same period in 2000. We purchased approximately $2.1 million of property and
equipment during the first quarter of 2001. We expect to acquire or lease
additional equipment in connection with future research and development
activities. We are also expending cash in the construction of our new 43,500
square foot medicinal chemistry building adjacent to our principal offices and
laboratory buildings in South San Francisco. We expect the building to be
completed in the second half of 2001 and to relocate some of our employees from
our off-campus medicinal chemistry building to the new building. At March 31, 2001,
we have incurred approximately $2.9 million on the construction and have
commitments totaling approximately $5.0 million. In April, we were notified
of a commitment to provide the company with a building construction loan for
a maximum of $11.0 million loan at prime plus one percent for up to 15 months
to complete the construction of this building. The drug development process is expensive and will require
that we raise money in the future until our company begins to generate
substantial product or royalty revenues, if ever. We believe that existing cash,
short-term investments, revenues from existing collaborations, potential
proceeds from the liquidation of our long-term equity investments in DPI and
DNAS, and potential additional licensing revenues will enable us to continue
current and planned operations for 18-24 months. We continue to actively pursue
a variety of financing alternatives. There can be no assurances that we can
liquidate our investments in a timely manner, or that the proceeds from these
investments will be adequate to meet our requirements to fund operations.
Finally, the senior secured convertible notes are collateralized by
approximately 6.7 million shares of the DPI stock we own; accordingly, at such
time that the DPI shares are liquidated, a substantial portion of the proceeds
may be used to retire the debt. In July 2000, we completed a sale of $10 million of our
common stock, under a shelf registration relating to the offer and sale of up to
$50 million of our common stock. The shares of common stock were sold at a
discounted weighted average price of $6.10 to Acqua Wellington North American
Equities Fund, Ltd.. Under the agreement with Acqua Wellington, we may,
after additional SEC filings in accordance with federal securities laws,
and at our discretion, issue and sell to Acqua Wellington up to an
additional $40 million of common stock, at a price per share based on the daily
volume weighted average price. In addition, we may also grant to Acqua
Wellington a right to purchase additional shares up to an amount equal to the
number of shares we elect to sell during that period. We expect that we will need to continue to raise money for a
number of years until we achieve, if we ever achieve, substantial product or
royalty revenues. We expect to seek additional funding through new
collaborations, the extension of existing collaborations, through sale of our
interests in DPI and DNAS, or through public or private equity or debt
financings. We cannot be certain that additional funding will be available or
that the terms will be acceptable. Existing stockholders will experience
dilution of their investment if we raise additional funds by issuing equity. If
adequate funds are not available, we may delay, reduce or eliminate any of our
research or development programs. Furthermore, we may obtain funds through
arrangements with collaborative partners or others that require us to give up
rights to technologies or products that we would otherwise seek to develop or
commercialize ourselves. Certain Business Risks We are at an early stage of development and will need a
substantial amount of additional funding to continue to prosecute our research
and development programs. Our proprietary research programs are, in many cases,
several years from clinical development and require substantial additional
research and development. All of our proposed products are in research or
development and will require significant additional research and development
efforts prior to any commercial use, including extensive and costly pre-clinical
and clinical testing, as well as lengthy regulatory approval involving many
complexities. Our research and development efforts may not be successful, our
proposed products may not prove to be safe and efficacious in clinical trials,
and no commercially successful products may ultimately be developed by us. In
addition, many of our currently proposed products are subject to development and
licensing arrangements with our collaborators. Therefore, we are dependent in
many cases on the research and development efforts of these collaborators.
Moreover, in cases where we are the licensor of its research programs, we are
entitled only to a portion of the revenues, if any, realized from the commercial
sale of any of the proposed products covered by the collaborations. We have
experienced significant operating losses since inception and expect to incur
significant operating losses over at least the next several years. The
development of our proposed products will require a commitment of substantial
funds to conduct these costly and time-consuming activities, which funds may not
be available. Should our collaborators or we fail to perform in accordance
with the terms of the applicable agreements, any consequent loss of revenue
under the collaboration agreements could have a material adverse effect on our
business, financial condition and results of operations. The proposed products
under development by we have never been manufactured on a commercial scale and
it is possible that proposed products may not be able to be manufactured at a
cost or in quantities necessary to make them commercially viable. We have no
sales, marketing or distribution capability for its proposed products. If any of
the products subject to our collaborative agreements involving licenses or our
research programs are successfully developed, we must rely on our collaborators
to market the products. We cannot ensure that any collaborator's marketing
efforts would be successful. If we develop any products which are not subject to
collaborative agreements under which our research partner is the marketer, we
must either rely on other pharmaceutical companies to market the products or we
must develop a marketing and sales force with technical expertise and supporting
distribution capability in order to market the products directly. We cannot
guarantee that its marketing efforts would be successful. The foregoing risks reflect our early stage of development
and the nature of its industry and products. Also inherent in our stage of
development are a number of additional risks, including competition, the
substantially greater financial resources of a number of its competitors,
uncertainties regarding protection of patents and proprietary rights, government
regulation, uncertainties related to clinical trials and health care reform and
the potential volatility of our stock price. These risks and uncertainties are
discussed further in "Items 1. Business - What Factors Could Cause Our Results
to Differ Significantly From Those You Might Expect?" and " - What Other Matters
Should Stockholders Consider with Respect to the Company?" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2000, filed by us
with the Securities and Exchange Commission on March 30, 2001. ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT
MARKET RISK The company's exposure to market risk is principally
limited to its cash equivalents and investments that have maturities of less
than one year. We maintain a non-trading investment portfolio of
investment grade, liquid debt securities that limits the amount of credit
exposure to any one issue, issuer or type of instrument. The securities in our
investment portfolio are not leveraged, are classified as available-for-sale
and are therefore subject to interest rate risk. We currently
do not hedge interest rate exposure. We are subject to market rate risks due to fluctuations in interest rates and
equity markets. All of our long-term debt is in the form of fixed-rate notes
with original maturities ranging over 4 years. Accordingly, fluctuations in
interest rates can lead to fluctuations in the fair value of such instruments.
We have not entered into financial derivatives to reduce its exposure to
interest rate risks. PART II. -- OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS None ITEM 2. CHANGES IN SECURITIES None ITEM 3. DEFAULTS UPON SENIOR SECURITIES None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS None ITEM 5. OTHER INFORMATION None ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K (a) EXHIBITS Exhibit Number Description 3.1 Amended and Restated Certificate of Incorporation. Previously filed on Form
10-K for the year ended March 31, 1998 and incorporated by reference. 3.2 Amended and Restated Bylaws. Previously filed on a Form S-1 registration
statement (33-69972) filed October 5, 1993 and incorporated by reference. 3.3 Registrant's Certificate of Designation of Series A Junior Participating
Preferred Stock. Previously filed on Form 8-K dated October 8, 1998 and
incorporated by reference. 4.1 Rights Agreement dated as of October 8, 1998, among Axys and ChaseMellon
Shareholders Services, LLC. Previously filed on Form 8-K dated October 8, 1998
and incorporated by reference. 4.2 Form of Rights Certificate. Previously filed on Form 8-K dated October 8,
1998 and incorporated by reference. 4.3 Indenture, dated September 22, 2000, between U.S. Bank Trust National
Association and Axys. Previously filed on Form 8-K filed on September 28, 2000
and incorporated by reference. 4.4 Class A Common Stock Purchase Warrant, dated September 22, 2000, between
Delta Opportunity Fund Limited and Axys. Previously filed on Form 8-K filed on
September 28, 2000 and incorporated by reference. 4.5 Class B Common Stock Purchase Warrant, dated September 22, 2000, between
Delta Opportunity Fund Limited and Axys. Previously filed on Form 8-K filed on
September 28, 2000 and incorporated by reference. 10.54 Collaborative Research Agreement entered into June 12, 1995 by and between
Sequana and Boehringer Ingelheim, Int'l.(1) 10.147 Executive Employment Agreement, dated December 14, 2000, by and
between Douglas Altschuler and the registrant. 10.148 Amended and Restated Executive Employment Agreement, dated March 30, 2001,
by and between Daniel F. Hoth, M.D. and the registrant. 10.149 Amended and Restated Executive Employment Agreement, dated
March 28, 2001, by and between Michael C. Venuti, Ph.D. and the
registrant. 10.150 Amended and Restated Executive Employment Agreement, dated
March 27, 2001, by and between William J. Newell and the registrant. 10.151 Amended and Restated Executive Employment Agreement, dated
March 27, 2001, by and between David E. Riggs and the registrant. 10.152 Executive Employment Agreement, dated January 23, 2001, by and
between Paul J. Hastings and the registrant. 10.153 Pledge Agreement, dated January 23, 2001, by and between Paul
J. Hastings and the registrant. 10.154 Promissory Note, dated January 2, 2001, by and between Paul J.
Hastings and the registrant. _______________
(1) A redacted version of this agreement was originally filed as Exhibit
10.10 to the Sequana Therapeutics Form S-1 registration statement (File No. 33-93460),
(renumbered as Axys Exhibit 10.54 as a result of the merger between Axys
and Sequana) pursuant to a confidentiality order dated, July 31, 1995. The
order has expired and Axys is now filing an unredacted version of the
agreement. (b) REPORTS ON FORM 8-K
South San Francisco, California 94080
(Address of principal executive offices including zip code)
(Registrant's telephone number, including area code)
TABLE OF CONTENTS
PART I. Financial Information
Page No.
Item 1. Financial Statements
(unaudited)*
Condensed Balance Sheet
as of March 31, 2001 and December 31, 2000
Condensed Statements of Operations
for the three months ended March 31, 2001 and 2000
Condensed Statements of Cash Flows
for the three months ended March 31, 2001 and 2000
Notes to Condensed Financial Statements
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
PART II. Other Information
Item 1. Legal Proceedings
Item 2: Changes in Securities
Item 3: Defaults Upon Senior Securities
Item 4: Submission of Matters to a Vote of Security Holders
Item 5: Other Information
Item 6. Exhibits and Reports on Form 8-K
Signatures
CONDENSED BALANCE SHEETS
(In thousands)
March 31, December 31,
2001 2000(1)
----------- ------------
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents............................ $ 29,191 $ 41,247
Marketable investments............................... 239 529
Accounts receivable.................................. 750 --
Prepaid expenses and other current assets............ 3,160 2,890
----------- ------------
Total current assets......................... 33,340 44,666
Property and equipment, net............................ 11,780 10,983
Investment in equity-method investee................... 42,828 40,367
Other investments...................................... 15,007 15,007
Notes receivable from employees........................ 652 365
Debt issuance costs, net............................... 6,299 6,753
Other assets........................................... 804 555
----------- ------------
Total assets................................. $ 110,710 $ 118,696
=========== ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable..................................... $ 3,544 $ 5,406
Accrued compensation................................. 1,535 2,154
Other accrued liabilities............................ 2,346 2,503
Deferred revenue..................................... 362 229
Current portion of capital lease and notes........... 1,047 950
----------- ------------
Total current liabilities.................... 8,834 11,242
Capital lease obligations, noncurrent.................. 2,300 1,889
Subordinated notes..................................... 26,000 26,000
Other liabilities...................................... 1,919 --
Stockholders' equity:
Common stock......................................... 357,582 347,444
Accumulated other comprehensive loss................. (512) (524)
Accumulated deficit.................................. (285,413) (267,355)
----------- ------------
Total stockholders' equity................... 71,657 79,565
----------- ------------
Total liabilities and stockholders' euity.... $ 110,710 $ 118,696
=========== ============
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended
March 31,
------------------
2001 2000
-------- --------
Collaboration and license revenue.................... $ 3,070 $ 1,414
-------- --------
Operating expenses:
Research and development........................... 8,929 7,858
General and administrative......................... 3,242 2,814
Non-cash compensation (income) expense............. (1,051) --
Restructuring charge............................... -- (545)
-------- --------
Total operating expenses................... 11,120 10,127
-------- --------
Operating loss....................................... (8,050) (8,713)
Interest income...................................... 531 141
Interest expense..................................... (1,474) (176)
Equity interest in loss of equity-method investee.... (9,059) --
Other expense........................................ (978) --
-------- --------
Loss from continuing operations...................... (19,030) (8,748)
Cumulative effect of change in accounting principle.. 972 --
Income from operations of discontinued segments...... -- 256
-------- --------
Net loss............................................. $(18,058) $ (8,492)
======== ========
Basic and diluted net loss per share from
continuing operations.............................. $ (0.51) $ (0.27)
Basic and diluted net income per share from
cumulative effect.................................. 0.03 --
Basic and diluted income per share from
discontinued segments.............................. -- 0.01
-------- --------
Basic and diluted net loss per share................. $ (0.48) $ (0.26)
======== ========
Shares used in computing basic and diluted net
(loss) income per share............................ 37,345 32,067
======== ========
CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
Three Months Ended
March 31,
--------------------
2001 2000
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss................................................. $ (18,058) $ (8,492)
Adjustments to reconcile net loss to net cash
and cash equivalents used in operating activities:
Non-cash restructuring charge.......................... -- (545)
Non-cash compensation income........................... (1,051) --
Cumulative effect of a change in accounting principle.. (972) --
Other expense.......................................... 978 --
Interest expense on convertible debt................... 519 --
Depreciation and amortization.......................... 1,712 1,952
Options and warrants issued to consultants............. 161 --
Equity interest in loss of equity-method investee...... 9,059 --
Forgiveness of note receivable from employees.......... 13 191
Changes in assets and liabilities:
Accounts receivable.................................. (750) (75)
Inventory............................................ -- 186
Prepaid expenses and other current assets............ (270) (716)
Other assets......................................... 296 16
Accounts payable..................................... (1,862) (2,226)
Accrued compensation................................. (619) (323)
Other accrued liabilities............................ (156) (1,147)
Deferred revenue..................................... 133 (756)
--------- ---------
Net cash and cash equivalents used in
operating activities........................... (10,867) (11,935)
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Available-for-sale securities:
Maturities............................................. 202 3,080
Minority interest........................................ -- (409)
Transaction costs on disposal of segment................. -- (1,500)
Net purchase of property and equipment................... (2,055) (1,333)
Loan to officer.......................................... (300) --
--------- ---------
Net cash and cash equivalents used in
investing activities........................... (2,153) (162)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock............... 457 34,273
Proceeds from notes payable and capital lease financing.. 703 20,000
Principal payments on notes payable and capital leases... (196) (17,269)
--------- ---------
Net cash and cash equivalents provided by
financing activities........................... 964 37,004
--------- ---------
Net (decrease) increase in cash and cash equivalents..... (12,056) 24,907
Cash and cash equivalents, beginning of period........... 41,247 23,577
--------- ---------
Cash and cash equivalents, end of period................. $ 29,191 $ 48,484
========= =========
NOTES TO CONDENSED FINANCIAL STATEMENTS
March 31, 2001
(UNAUDITED)
Three Months Ended
March 31,
-------------------
DOLLARS IN THOUSANDS 2001 2000
- ------------------------------------ --------- ---------
Net sales........................... $ 9,524 $ 5,173
Loss from operations................ (3,455) (437)
Net loss............................ (2,201) (1,630)
Three Months Ended
March 31,
------------------
2001 2000
-------- --------
Net loss............................................. $(18,058) $ (8,492)
Other comprehensive income (loss).................... 12 (1)
-------- --------
Comprehensive loss................................... $(18,046) $ (8,493)
======== ========
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AXYS PHARMACEUTICALS, INC. |
(Registrant) |
Dated: May 14, 2001
By: | /s/ PAUL J. HASTINGS |
| |
Paul J. Hastings | |
President, Chief Executive Officer and Director (Principal Executive Officer) |
Dated: May 14, 2001
By: | /s/ DAVID E. RIGGS |
| |
David E. Riggs | |
Senior Vice President, Chief Financial Officer (Chief Accounting Officer and Principal Financial Officer) |
INDEX TO EXHIBITS
Exhibit Number |
Description |
3.1 |
Amended and Restated Certificate of Incorporation. Previously filed on Form 10-K for the year ended March 31, 1998 and incorporated by reference. |
3.2 |
Amended and Restated Bylaws. Previously filed on a Form S-1 registration statement (33-69972) filed October 5, 1993 and incorporated by reference. |
3.3 |
Registrant's Certificate of Designation of Series A Junior Participating Preferred Stock. Previously filed on Form 8-K dated October 8, 1998 and incorporated by reference. |
4.1 |
Rights Agreement dated as of October 8, 1998, among Axys and ChaseMellon Shareholders Services, LLC. Previously filed on Form 8-K dated October 8, 1998 and incorporated by reference. |
4.2 |
Form of Rights Certificate. Previously filed on Form 8-K dated October 8, 1998 and incorporated by reference. |
4.3 |
Indenture, dated September 22, 2000, between U.S. Bank Trust National Association and Axys. Previously filed on Form 8-K filed on September 28, 2000 and incorporated by reference. |
4.4 |
Class A Common Stock Purchase Warrant, dated September 22, 2000, between Delta Opportunity Fund Limited and Axys. Previously filed on Form 8-K filed on September 28, 2000 and incorporated by reference. |
4.5 |
Class B Common Stock Purchase Warrant, dated September 22, 2000, between Delta Opportunity Fund Limited and Axys. Previously filed on Form 8-K filed on September 28, 2000 and incorporated by reference. |
10.54 |
Collaborative Research Agreement entered into June 12, 1995 by and between Sequana and Boehringer Ingelheim, Int'l.(1) |
10.147 |
Executive Employment Agreement, dated December 14, 2000, by and between Douglas Altschuler and the registrant. |
10.148 |
Amended and Restated Executive Employment Agreement, dated March 30, 2001, by and between Daniel F. Hoth, M.D. and the registrant. |
10.149 |
Amended and Restated Executive Employment Agreement, dated March 28, 2001, by and between Michael C. Venuti, Ph.D. and the registrant. |
10.150 |
Amended and Restated Executive Employment Agreement, dated March 27, 2001, by and between William J. Newell and the registrant. |
10.151 |
Amended and Restated Executive Employment Agreement, dated March 27, 2001, by and between David E. Riggs and the registrant. |
10.152 |
Executive Employment Agreement, dated January 23, 2001, by and between Paul J. Hastings and the registrant. |
10.153 |
Pledge Agreement, dated January 23, 2001, by and between Paul J. Hastings and the registrant. |
10.154 |
Promissory Note, dated January 2, 2001, by and between Paul J. Hastings and the registrant. |
_______________
(1) A redacted version of this agreement was originally filed as Exhibit 10.10 to the Sequana Therapeutics Form S-1 registration statement (File No. 33-93460), (renumbered as Axys Exhibit 10.54 as a result of the merger between Axys and Sequana) pursuant to a confidentiality order dated, July 31, 1995. The order has expired and Axys is now filing an unredacted version of the agreement.
Exhibit 10.54
Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the securities
and exchange commission pursuant to rule 406 of the securities act of 1933, as
amended. COLLABORATIVE RESEARCH AGREEMENT
This Collaborative Research Agreement is entered effective as of June 12, 1995, by and between Sequana Therapeutics, Inc., a California corporation, having its principal place of business at 11099 North Torrey Pines Road, Suite 160, La Jolla, California 92037 ("Sequana"), and Boehringer Ingelheim International GmbH, a German corporation having its principal place of business at D-55216 Ingelheim am Rhein ("BI").
Recitals
Whereas, Sequana has generated data regarding the genetic basis of Asthma and Sequana and BI desire to collaborate in the investigation into the genetic basis of Asthma pursuant to the terms of this Agreement; and
Whereas, the goal of the collaboration is to identify the gene or genes responsible for Asthma with a view to BI developing products for the prevention or treatment of Asthma; and
Whereas
, the Parties wish to provide for the allocation of rights to therapeutic compounds, compositions and products and all diagnostic devices, compounds, kits and services as provided herein; andWhereas
, of even date herewith Sequana and BI have entered into a Stock Purchase Agreement pursuant to which BI has agreed to purchase, and Sequana has agreed to sell to BI, shares of Sequana Series F Preferred Stock.Now, Therefore, the Parties agree as follows:
As used herein, the following terms will have the meanings set forth below:
(i) is discovered by either Party, or a third party directed by the JRC, through studies with the Asthma Database; and
(ii) has been successfully cloned and sequenced by or for either Party; and
(iii) has been shown by or for either Party to be altered or deleted in coding, non-coding or control regions in individuals, resulting in or associated with the pathophysiological or functional changes causing, predisposing or suppressing the development of Asthma.
(i) Prompt payment or other trade or quantity discounts actually allowed and taken in such amounts as are customary in the trade, including private sector or governmental rebates such as Medicaid rebates or rebates to pharmaceutical benefit organizations or managed health care groups, directly relate to such;
(ii) Amounts repaid or credited by reason of timely rejections or returns;
(iii) Taxes (other than franchise or income taxes on the income of the selling Party), including any withholding taxes, directly related to such sale and actually paid; and
(iv) Transportation and delivery charges, including insurance premiums, actually incurred.
(a) Completion of genotyping and linkage analysis. Linkage for distinct loci determined at a maximal interval size (=flanking markers) of 5 cM, with LOD scores >3 or p values < 0.01 depending on the patient material (i.e., families or sib pairs) for linked markers. |
$1,000,000 |
|
(b) Completion of physical mapping containing greater than 95% of the minimal region, not to exceed the flanking markers described above. |
$1,000,000 |
|
(c) Successful identification of any Asthma Gene, up to a total of five (5) Asthma Genes. Successful identification shall be shown by isolation of a cDNA with at least one of the following characteristics: (i) significant sequence re-arrangements in the coding or the promoter region in affected individuals; or (ii) obvious disease-specific re-arrangements detected by SSCP, DGGE or other appropriate mutation detection technologies. |
||
For each of the first two Asthma Genes. |
$2,000,000 |
|
For each of the third, fourth and fifth Asthma Genes. |
$1,000,000 |
|
No further milestones shall be due for any additional Asthma Genes, beyond the first five (5) Asthma Genes, subject to Article 2.5.2. |
Notwithstanding the above, payments for successful identification shall only be made with respect to Gene sequences which have not previously been patented by a third party or publicly shown to be altered in asthma patients at the time of the identification of such sequences.
(i) facilitate the exchange of Results between the Parties;
(ii) coordinate and plan the respective Research efforts of the Parties;
(iii) direct the Research, and monitor and assess the progress of such Research in relation to the stated goals and objectives of this Agreement;
(iv) advise and assist in the resolution of any scientific or technical difficulties which are experienced by either Party in performing the Research;
(v) consider Results, inventions and discoveries arising out of the Research including the determination and acknowledgment of whether or not an identified sequence is an Asthma Gene;
(vi) review and attempt to resolve any disputes relating to a proposed publication of material related to the Research;
(vii) review and attempt to resolve any other disputes between the Parties;
(viii) prepare each Annual Research Plan;
(ix) adjust the size and composition of the Research team of Sequana, and advise BI regarding the size and composition of its Research team;
(x) stipulate when research milestones have been achieved according to Article 2.5; and
(xi) prepare an annual estimate of payments to be made by BI to Sequana under the terms of this Agreement.
Type 1 Product |
Type 2a Product |
Type 2b Product |
Type 3 Product |
Type 4 Product |
|
IND filing |
$ 2 M |
$2M |
$ 1 M |
$ 1 M |
$ 0.5M |
NDA/PLA filing |
$ 4 M |
$ 3 M |
$2M |
$2M |
$ 2 M |
NDA/PLA approval |
$ 8 M |
$4M |
$2M |
$2M |
$ 2 M |
The milestone payments made pursuant to this Article 4.1 shall be non-refundable but creditable against royalties due Sequana pursuant to Article 4.2 below, beginning in the year following the third full calendar year of commercial sale of any BI Product, up to a maximum of fifty percent (50%) of the royalties due in any year.
Royalty |
|
Type I Product |
12% |
Type 2a Product |
5% |
Type 2b Product |
3% |
Type 3 Product |
2% |
Type 4 Product |
2% |
In the event that a commercially significant competitive product that acts on the same intervention point as a Type 3 or Type 4 Product is introduced by a party other than BI or its Affiliates or sublicensees into a geographic market in which BI has Net Sales, the royalties due to Sequana on such Type 3 or Type 4 Product in that market shall be reduced to 1% of Net Sales, from the date the competitive product is introduced into the particular market, as long as such product is sold in that market, and such royalties shall not be subject to any further reductions or offsets. In the event such competitive product that acts on the same intervention point as a Type 1, Type 2a or Type 2b Product is introduced by a party other than BI or its Affiliates or sublicensees into such market, the Parties will meet to discuss whether a reduction should be made in the royalties payable to BI; provided, no such reduction shall occur without the mutual written consent of the Parties.
In order to be treated as Confidential Information for purposes of this Agreement, each Party shall use its best efforts to summarize in writing and deliver to the other Party within sixty (60) days following disclosure, any Confidential Information that is disclosed orally or visually and which the disclosing Party wishes the receiving Party to maintain under an obligation of non-disclosure under Article 8.1.
Nothing in this Article 8 shall prevent a Party from disclosing Confidential Information received hereunder or generated by such Party by itself to government authorities to the extent necessary, in the good faith opinion of such Party, to receive government permission to make, have made, use, or sell, BI Products or Sequana Products, as the case may be, or as required in connection with the exercise of the licenses granted under Article 5.
In the event a Party brings an infringement action, the other Party shall cooperate fully and completely. Neither Party shall have the right to settle any patent infringement litigation under this Article 10.6.4, in a manner that diminishes the rights or interests of the other Party without the consent of such other Party. The costs of any litigation commenced pursuant to this Article 10.6.4, including attorneys' fees and expenses, shall be borne equally by the Parties if joint prosecution was agreed upon, with such costs to be accounted for in equalizing payments to be made on a quarterly basis, or shall be borne by the single Party who prosecutes the infringement. Only out- of-pocket costs shall be accounted for and reimbursed under this Article 10.6.4, without an allocation for internal resources devoted to litigation. Except as otherwise agreed to by the Parties as part of a cost sharing arrangement, any recovery realized as a result of such litigation shall be shared equally by the Parties if joint prosecution was agreed upon or shall be the sole property of the single Party prosecuting the infringement.
To Sequana: |
Sequana Therapeutics, Inc. |
11099 North Torrey Pines Road, Suite 160 |
|
La Jolla, California 92037 |
|
Attn: Chief Executive Officer |
|
To BI: |
Boehringer Ingelheim International GmbH |
D-55216 Ingelheim am Rhein |
|
Attn: Corporate Licensing |
|
cc: Legal Department |
[THIS SPACE INTENTIONALLY LEFT BLANK]
In Witness Thereof; the Parties hereto set their hands to this Agreement.
Sequana Therapeutics, Inc.
By: /s/ Kevin J. Kinsella
Name: Kevin J. Kinsella
Title: Chief Executive Officer
Date:_____________________________
Boehringer Ingelheim International GmbH
By: /s/ Muller /s/ D. G. Mitchard
Name: Muller Mitchard
Title: Authorized figuratives
Date:_____________________________
By:________________________________
Name:______________________________
Title:_____________________________
Date:______________________________
Exhibit A
Sequana
Therapeutics
Boehringer
Ingelheim
Isolation of Asthma & Atopy
Susceptibility Genes
Research Plan
1995-1996
Outline Research Proposal
1995-1996
Strategic Overview
Bronchial hyperresponsiveness and atopic asthma are polygenic conditions resulting from complex interactions of genes and environmental agents. Sequana Therapeutics has undertaken to isolate and characterize genes involved in asthma etiology. The current asthma program is focused on identifying genes contributing to bronchial hyperresponsiveness (BHR) and frank asthma in humans. Several large unique asthmatic patient populations have been ascertained in this effort, and a complete genome scan has lead to identification of at least two novel genetic loci influencing BHR/frank asthma. In late 1995 we will augment this ongoing program using several complementary patient populations selected for allergic asthma, or atopy.
The research plan for 1995 and 1996 has three primary foci:
1. Fine genetic mapping and mutation detection in the two BHR loci that have been identified and validated;
2. Additional genome-wide screening for BHR and frank asthma susceptibility loci, followed by verification of linkage and linkage disequilibrium in independent patient samples;
3. Genome-scan and candidate gene evaluation of atopy genes in genetically informative samples of phenotypically and ethnically matched atopic families.
Current Progress
Patient Collection: Airway Hyperreactivity
Tristan da Cunha. To date, Sequana has collected BHR, frank asthma, and atopy-related phenotypes from four independent samples. The cornerstone of these samples is entire population of the island of Tristan da Cunha. Tristan da Cunha, a small South Atlantic island situated between Rio de Janeiro, Brazil and Capetown, South Africa, is inhabited by 282 living descendants of seven British, American, Italian, and Dutch founders. Current inhabitants reflect ten generations of intense inbreeding, which has resulted in kinship resemblances of at least first cousin levels for all individuals. This degree of inbreeding, coupled with at least one recorded case of asthma in the island founders, has led to a population prevalence of 20% -50% for frank asthma, BHR, and allergic response. The founder effect in this population renders it the most unique and powerful asthma patient resource in the world.
DNA and asthma and atopy phenotypes have been obtained from nearly all (269/282) living inhabitants of Tristan da Cunha. The primary phenotypes for analysis include lifetime history of asthma, age of asthma onset, methacholine challenge response, smoking history, and skin prick tests for twelve common allergens.
Replication Samples: Toronto. A major emphasis of our research strategy for identifying novel genetic loci is to validate suggestive linkages by replication with independent patient samples. Accordingly, Sequana has established two cohorts of sib-pair samples for replication with Tristan da Cunha. The first comprises 110 Caucasian sib pairs drawn from Toronto, Ontario, Canada. Toronto sib-pairs were ascertained based on the following criteria: (i) proband having methacholine PC20 < 4 mg/ml; (ii) availability of at least one sibling of the proband, either affected or unaffected; (iii) at least one living parent from whom DNA could be obtained. Phenotypes obtained from this cohort include: Asthma history questionnaire, methacholine challenge test, total IgE level, skin prick responses to 10 common allergens, and smoking history.
QIMR. The second replication sample consists of 221 dizygotic twin pairs, obtained via a collaboration with the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia. This sample was drawn from a registry of over 4000 twin pairs, with ascertainment based on positive history of wheezing followed by physician diagnosis of asthma or atopy. Available phenotypes include histamine challenge responses, physician diagnosis of asthma and atopy, skin prick responses to twelve common allergens, total IgE, smoking history and other respiratory-related environmental exposures, and over 200 additional anthropometric, demographic, and medical variables obtained by questionnaire and physician interview.
Chinese Family. BHR, asthma, and atopy phenotypes also have been obtained from a large family of 174 Chinese individuals living in Toronto, Ontario. This family was identified based on a high proportion of asthmatics (> 25%). DNA has been extracted from all individuals. This family is not used as a replication of Tristan da Cunha due to ethnic differences; rather, it is employed to evaluate mutation ages and variability among ethnicities.
Linkage Analysts
Genome Scan. A 20 cM genome scan of more than 240 microsatellite markers has been completed on the Tristan da Cunha population. Linkage analyses of these data have yielded 11 possible linkages for airway hyperreactivity at a probability level of 51% or less. Many of these are likely to be false positives due to random statistical fluctuation; however, two linkages exceed the 0.5% level, and two others occur with probability less than 0.01%. These latter findings correspond to LOD scores greater than 4.0. These loci are henceforth denoted WHZ1 and WHZ2.
WHZ1 Saturation. The chromosomal regions surrounding the initial WHZ1 and WHZ2 markers have been saturated with additional polymorphic genetic markers. Most of the work in this saturation has focused on WHZ1, owing to stronger initial evidence for linkage (probability = .00004) and an attractive candidate gene very near the linked marker. Saturation marker mapping of WHZ2 is ongoing. The resulting genetic map of WHZ1 includes markers spaced in intervals no greater than 5 cM across a possible linked region of approximately 30 cM. Sib-pair and affected pedigree member linkage analyses of the saturation markers yielded confirmatory evidence for linkage and refined the genetic interval to 12 cM. Eight additional markers spanning the 12 cM region have been identified and developed. These are shown below, with genetic distances by the Tristan da Cunha population.
Replication. The saturation markers have been genotyped in the Toronto and QIMR sib-pair samples. Sib-pair analyses of both samples yielded significant evidence for linkage to multiple markers in this region (p <.05). Control markers located in unlinked regions of the genome provided appropriate negative evidence for linkage. In all samples, WHZ1 linkage was obtained with frank asthma and positive airway hyperreactivity, but not for available measures of atopy (skin prick tests in all samples; IgE in Toronto and QIMR). This replication in three independent samples represents the strongest evidence ever compiled for an asthma susceptibility gene.
WHZ1a candidate gene. It is noteworthy that the strongest evidence for linkage in the Toronto sib-pair and QIMR samples is not obtained at the initial marker identified in Tristan da Cunha (marker "D" shown above). Rather, the most significant marker is situated approximately 1.3 cM proximal, shown as marker "C" above. Furthermore, the QIMR sample, which is our largest outbred sib-pair sample, yields a further refined interval for linkage, spanning approximately 3.6 cM on the map above (markers "B" to "E"). This interval contains an attractive candidate gene for airway hyperreactivity, which we denote WHZ1a. This candidate gene is less than 0.5 cM from marker "C".
Physical Mapping and Sequencing
Cloning of Genomic Regions. In the physical mapping core group at Sequana, yeast artificial chromosomes (YACS) containing genetic markers linked to each asthma locus are identified by routine PCR methods. A contig of overlapping clones is then assembled using sequence tagged sites (STSs) to establish overlaps between the clones, fluorescence in situ hybridization (FISH) to assay for chimerism, and pulse field gel electrophoresis (PFGE) to size the clones. A YAC contig for the WHZ1 asthma locus (shown below) has been completed. Seven known genes are in this contig. In specific regions of interest within each YAC contig, for example near a candidate gene, cosmid contigs are also being assembled. A cosmid contig across the WHZ1a candidate gene within the WHZ1 region is 80% complete.
Identification of New Genetic Markers. Polymorphic microsatellites (CA)n repeats have been identified from both YACS and cosmids in the WHZ1 region. These markers have contributed to the genetic refinement of the WHZ1 interval. A novel (CA)n repeat polymorphism has been identified in a WHZ1a intron.
Mutation Detection. Initial screening of mutations in WHZ1a is presently underway. Mutation screening of patient DNAs is conducted by several complementary methods:
1. Single stranded conformational polymorphism (SSCP) evaluation is used to detect polymorphism in the coding regions of WHZ1a. This method lends itself to large scale, fast analysts of several candidate genes concurrently.
2. PCR and sequencing of exons of patient DNAs and controls. This provides a very detailed analysis of a particular segment of sequence and can be used to reveal the exact nature of a polymorphism. or mutation identified by methods like SSCP.
3. RT-PCR and Northern blotting are underway to verify the size of candidate gene transcripts and level of expression in available tissues. Analysis of splice variants will also be undertaken.
Future Activities
Overview. Four major areas of emphasis are targeted for the asthma program in 1995-1996. These include:
(i) Gene verification and mutation detection of WHZ1. Although WHZ1a is an attractive candidate gene, there are at least 6 other genes in the region. Primary effort will be devoted to establishing the asthma susceptibility gene(s) in the WHZ1 region and identifying mutations in this gene. This involves both continued physical mapping of WHZ1a and physically locating and screening other genes in cloned regions. WHZ1a polymorphisms/mutations will be characterized by the end of September 1995.
(ii) Marker development, linkage replication, and gene localization of WHZ2. The same approach taken in WHZ1 will be applied to the second strong linkage arising in Tristan da Cunha, WHZ2. This includes construction of a fine genetic map of less than 5 cM, developing
additional markers if necessary, replicating linkage and linkage disequilibrium across the markers, determining all known genes and ESTs, and physically mapping the hyperreactivity gene in the region. Marker development and linkage replication will be completed in 1995. Gene localization will begin in 1995 and continue into 1996.
(iii) Identification of other airway hyperreactivity loci. As described above, there are a number of additional asthma loci showing suggestive evidence for linkage. These chromosome regions will be evaluated genetically by replication and by marker development for saturation. Furthermore, a genome scan is planned for the QIMR sample in order to complement the inbred Tristan da Cunha population. The follow-up analyses of suggestive linkages and the 20 cM scan of QIMR will continue through 1996. The QIMR sample numbers can easily be expanded.
(iv) Development of an atopy program. Characterizing genes predisposing to atopy versus asthma is crucial to the research program and to subsequent development of diagnostic and therapeutic agents. Access to additional patient populations for genome scanning and linkage replication is be established at present. The cornerstone of this effort will be a collaboration with Dr. David Marsh of Johns Hopkins University. Dr. Marsh is a world leader in allergic asthma and has collected a very large number of families for identification of atopy genes. The samples of Dr. Marsh, in combination with our QIMR twin sample, provide a complete atopy program, allowing sufficient resources for linkage replication, fine mapping, and mutation characterization. The programme would follow the route of a genome scan with special emphasis on candidate gene regions.
Specific Activities. The Sequana research program is split into five "core" areas, consisting of (1) DNA Collection; (2) Genetic Mapping; (3) Physical Mapping; (4) DNA Sequencing and Mutation Analysis; (5) Gene Characterization and Assay Development. Specific activities in each of these core areas are described below.
DNA Collection
Genetic Mapping
Physical Mapping and Sequencing
Gene Characterization
Exhibit B
Asthma Patient Recruitment
Sequana has entered into agreements with the following groups prior to the Effective Date to acquire patient samples for the study of asthma.
Signed Agreements |
Families |
Fixed Cost |
Variable Cost |
Total Cost |
Fudan University, PRC |
100 |
$ 15,000 |
$ 40,000 |
$ 55,000 |
RenJi Hospital, PRC |
125 |
0 |
25,000 |
25,000 |
Shanghai 1st Hospital, PRC |
125 |
0 |
25,000 |
25,000 |
Queensland Inst. Med. Res. |
220 |
121,000 |
121,000 |
242,000 |
$347,000 |
Amount to be Negotiated and Approved by the JRC
SLRI (China, Toronto) |
100 |
100,000 |
0 |
$100,000 |
COLLABORATIVE RESEARCH AGREEMENT
between
SEQUANA THERAPEUTICS
and
BOEHRINGER INGELHEIM
INTERNATIONAL GmbH
Table of Contents
Page
ARTICLE 1. DEFINITIONS *
ARTICLE 2. RESEARCH *
ARTICLE 3. JOINT RESEARCH COMMITTEE *
ARTICLE 4. DEVELOPMENT MILESTONES AND ROYALTIES *
ARTICLE 5. GRANT OF LICENSES *
ARTICLE 6. EXCLUSIVITY *
ARTICLE 7. DEVELOPMENT *
ARTICLE 8. CONFIDENTIALITY *
ARTICLE 9. PUBLICATION *
ARTICLE 10. PROPERTY RIGHTS AND PATENTS *
ARTICLE 11. INDEMNITY AND INSURANCE *
ARTICLE 12. TERMINATION *
ARTICLE 13. ASSIGNMENT *
ARTICLE 14. REPRESENTATIONS AND WARRANTIES *
ARTICLE 15. NOTICES *
ARTICLE 16. MISCELLANEOUS *
Exhibit 10.147
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement ("Agreement") is entered into as of the 14th day of December, 2000 (the "Effective Date"), by and between Douglas Altschuler ("Executive") and Axys Pharmaceuticals, Inc. (the "Company").
WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive's services; and
WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits.
NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
For purposes of the, Agreement, the following terms arc defined as follows:
provided, however, that if any of the foregoing events under clauses (a), (b), (c) or (d) above is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.
The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company. Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee's employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company. Executive's duties under this Article 7 shall survive termination of Executive's employment with the Company and the termination of this Agreement.
IN WITNESS WHEREOF, the parties have executed this Agreement on the day and year first above written.
AXYS PHARMACEUTICALS, INC.
By: Paul J. Hastings
Date: March 26, 2001
Accepted and agreed this
26th day of March, 2001
/s/ Douglas Altschuler
DOUGLAS ALTSCHULER
Exhibit A: Release (Individual Termination)
Exhibit B: Release (Group Termination)
Exhibit C: Proprietary Information and Inventions Agreement
EXHIBIT A
RELEASE
(INDIVIDUAL TERMINATION)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows:
"A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor."
I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation, claims pursuant to any federal, state or local law or cause, of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended, the federal Americans with Disabilities Act of 1990, the California Fair Employment and Housing Act, as amended, tort law, contract law, statutory law, common law, wrongful discharge, discrimination fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the patties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after this Release is executed by me.
DOUGLAS ALTSCHULER
Date:_______________________
EXHIBIT B
RELEASE
(GROUP TERMINATION)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement. I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended, the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"), the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990, the California Fair Employment and Housing Act, as amended; tort law, contract law; statutory law; common law, wrongful discharge, discrimination, fraud, defamation, emotional distress, and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver arid release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release, (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier), (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release: (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
DOUGLAS ALTSCHULER
Date:_______________________
EXHIBIT C
PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
Exhibit 10.148
AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement ("Agreement") is entered into as of the 30th day of March, 2001 (the "Effective Date"), by and between Daniel F. Hoth, M.D. ("Executive") and Axys Pharmaceuticals, Inc. (the "Company").
Whereas, the Company desires to continue to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive's services; and
Whereas, Executive wishes to continue to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and
Whereas, Executive and the Company wish to amend and restate that Employment Agreement entered into between the two parties as of ____________, 2000 (the "Prior Agreement").
Now, Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
For purposes of the Agreement, the following terms are defined as follows:
provided, however, that if any of the foregoing events under clauses (a), (b), (c) or (d) above is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.
The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee's employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company. Executive's duties under this Article 7 shall survive termination of Executive's employment with the Company and the termination of this Agreement.
8.11 Amended and Restated Agreement. This Agreement shall supersede in its entirety the Prior Agreement as of the Effective Time.
In Witness Whereof, the parties have executed this Agreement on the day and year first above written.
Axys Pharmaceuticals, Inc.
By: Paul J. Hastings
Date: March 26, 2001
Accepted and agreed this
30th day of March, 2001
/s/ Daniel F. Hoth
Daniel F. Hoth, M.D.
Exhibit A: Release (Individual Termination)
Exhibit B: Release (Group Termination)
Exhibit C: Proprietary Information and Inventions Agreement
Exhibit A
RELEASE
(Individual Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after this Release is executed by me.
Daniel F. Hoth, M.D.
Date:_____________________
Exhibit B
RELEASE
(Group Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
Daniel F. Hoth, M.D.
Date:________________________
Exhibit C
Proprietary Information and Inventions Agreement
Exhibit 10.149
AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT
This Amended and Restated Executive Employment Agreement ("Agreement") is entered into as of the 28th day of March, 2001 (the "Effective Date"), by and between Michael C. Venuti, Ph.D. ("Executive") and Axys Pharmaceuticals, Inc. (the "Company").
Whereas, the Company desires to continue to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive's services; and
Whereas, Executive wishes to continue to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and
Whereas, Executive and the Company wish to amend and restate that Employment Agreement entered into between the two parties as of December 14, 1999 (the "Prior Agreement").
Now, Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
For purposes of the Agreement, the following terms are defined as follows:
provided, however, that if any of the foregoing events under clauses (a), (b), (c) or (d) above is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.
3.5 Debt Forgiveness.
Effective Date |
Debt Forgiveness |
8/__/01 |
$60,000 |
8/__/02 |
$60,000 |
8/__/03 |
$60,000 |
8/__/04 |
$60,000 |
8/__/05 |
$60,000 |
Any amounts under the Note not otherwise forgiven or previously paid by Executive shall be paid by Executive to the Company on August __, 2005 or such earlier date as provided in the Note.
The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee's employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company. Executive's duties under this Article 7 shall survive termination of Executive's employment with the Company and the termination of this Agreement.
8.11 Amended and Restated Agreement. This Agreement shall supersede in its entirety the Prior Agreement as of the Effective Date.
In Witness Whereof, the parties have executed this Agreement on the day and year first above written.
Axys Pharmaceuticals, Inc.
By: /s/ Paul J. Hastings
Date: March 27, 2001
Accepted and agreed this
28th day of March, 2001
/s/ Michael C. Venuti
Michael C. Venuti, Ph.D.
Exhibit A: Release (Individual Termination)
Exhibit B: Release (Group Termination)
Exhibit C: Proprietary Information and Inventions Agreement
Exhibit A
RELEASE
(Individual Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after this Release is executed by me.
Michael C. Venuti, Ph.D.
Date:____________________
Exhibit B
RELEASE
(Group Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
Michael C. Venuti, Ph.D.
Date:________________________
Exhibit C
Proprietary Information and Inventions Agreement
Exhibit 10.150
AMENDED
AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
This Amended and Restated Executive Employment Agreement ("Agreement") is entered into as of the 27th day of March, 2001 (the "Effective Date"), by and between William J. Newell ("Executive") and Axys Pharmaceuticals, Inc. (the "Company").
Whereas, the Company desires to continue to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive's services;
Whereas, Executive wishes to continue to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and
Whereas, Executive and the Company wish to amend and restate that Employment Agreement entered into between the two parties as of March 14, 1999 (the "Prior Agreement").
Now, Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
For purposes of the Agreement, the following terms are defined as follows:
The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee's employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company. Executive's duties under this Article 7 shall survive termination of Executive's employment with the Company and the termination of this Agreement.
In Witness Whereof, the parties have executed this Agreement on the day and year first above written.
Axys Pharmaceuticals, Inc.
By: /s/ Paul J. Hastings
Date: March 27, 2001
Accepted and agreed this
27th day of March, 2001
/s/ William J. Newell
William J. Newell
Exhibit A: Release (Individual Termination)
Exhibit B: Release (Group Termination)
Exhibit C: Proprietary Information and Inventions Agreement
Exhibit A
RELEASE
(Individual Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after this Release is executed by me.
William J. Newell
Date:___________________________
Exhibit B
RELEASE
(Group Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
William J. Newell
Date:_____________________________
Exhibit C
Proprietary Information and Inventions Agreement
Exhibit 10.151
AMENDED
AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment Agreement ("Agreement") is entered into as of the 27th day of March, 2001 (the "Effective Date"), by and between David E. Riggs ("Executive") and Axys Pharmaceuticals, Inc. (the "Company").
Whereas, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive's services;
Whereas, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and
Whereas, Executive and the Company wish to amend and restate that Employment Agreement entered into between the two parties as of August 9, 2000 .
Now, Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
For purposes of the Agreement, the following terms are defined as follows:
provided, however, that if any of the foregoing events under clauses (a), (b), (c) or (d) above is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.
The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.
The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive's right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.
While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee's employment in order to become an employee, consultant or independent contractor to or for any competitor of the Company. Executive's duties under this Article 7 shall survive termination of Executive's employment with the Company and the termination of this Agreement.
In Witness Whereof, the parties have executed this Agreement on the day and year first above written.
Axys Pharmaceuticals, Inc.
By: /s/ Paul J. Hastings
Date: March 27, 2001
Accepted and agreed this
27th day of March, 2001
/s/ David E. Riggs
David E. Riggs
Exhibit A: Release (Individual Termination)
Exhibit B: Release (Group Termination)
Exhibit C: Proprietary Information and Inventions Agreement
Exhibit A
RELEASE
(Individual Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth (8th) day after this Release is executed by me.
David E. Riggs
Date:_______________________
Exhibit B
RELEASE
(Group Termination)
Certain capitalized terms used in this Release are defined in the Executive Employment Agreement (the "Agreement") which I have executed and of which this Release is a part.
I hereby confirm my obligations under the Company's proprietary information and inventions agreement.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, in consideration of benefits I will receive under the Agreement, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me pursuant to the Company's indemnification obligation pursuant to agreement or applicable law.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
David E. Riggs
Date:________________________
Exhibit C
Proprietary Information and Inventions Agreement
Exhibit 10.152
EMPLOYMENT AGREEMENT
This Employment Agreement ("Agreement") is entered into as of this 23rd day of January, 2001 (the "Effective Date"), by and between Paul Hastings ("Executive") and Axys Pharmaceuticals, Inc., a Delaware corporation (the "Company").
Whereas, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such services; and
Whereas, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits.
Now, Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
1. Employment By The Company.
1.1 The Company agrees to employ Executive in the position of President and Chief Executive Officer of the Company. During Executive's employment with the Company, Executive will devote his best efforts and substantially all of his business time and attention to the business of the Company.
1.2 Executive shall serve in an executive capacity and shall perform such duties as are customarily associated with his then current titles, consistent with the Bylaws of the Company and as required by the Company's Board of Directors (the "Board").
1.3 The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this Agreement differ from or are in conflict with the Company's general employment policies or practices, this Agreement shall control.
1.4 The Company and Executive each acknowledge that either party has the right to terminate Executive's employment with the Company at any time for any reason whatsoever, with or without Cause or advance notice. This at-will employment relationship cannot be changed except in a writing signed by both Executive and a majority of the Board.
2. Compensation.
2.1 Salary. Executive shall receive, for services to be rendered under this Agreement, an annualized base salary ("Base Salary") equal to $400,000. Such Base Salary shall commence as of the Effective Date, and shall be payable in installments consistent with the Company's payroll policies. Executive's Base Salary shall be reviewed at least annually by the Board, and in the Board's sole discretion, may be increased at any time.
2.2 Termination.
(a) In the event Executive's employment terminates for any reason other than death, disability, a termination upon a Change of Control, a voluntary termination not for Good Reason, or a termination for Cause, upon execution of an effective release in the form attached hereto as Exhibit A: (i) Executive shall receive twelve (12) monthly payments each equal in amount to one-twelfth (1/12th) of the sum of (x) the full amount of one year's Target Bonus (at the level in effect at that time) and (y) his then Base Salary; (ii) additional Stock Options (as defined below) shall, immediately prior to Executive's termination of employment, become vested with respect to that number of shares which would have become vested had Executive remained in continuous service with the Company for an additional twelve (12) months following the date of Executive's termination of employment; and (iii) for a period of twelve (12) months (or until comparable benefits coverage becomes available to Executive, if sooner), the Company shall pay the costs associated with the continuation of Executive's medical, dental, and vision benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA") as in effect immediately prior to Executive's termination of employment.
(b) For purposes of this Agreement, "Good Reason" means that any of the following are undertaken without Executive's express written consent: (i) the assignment to Executive of any duties or responsibilities which result in any diminution or adverse change of Executive's position, status or circumstances of employment; (ii) a reduction by the Company in Executive's Base Salary; (iii) the taking of any action by the Company which would adversely affect Executive's participation in, or reduce Executive's benefits under, the Company's benefit plans (including equity benefits) as of the time this Agreement is executed, except to the extent the benefits of all other executive officers of the Company are similarly reduced; (iv) a relocation of Executive's principal office to a location more than forty (40) miles from 180 Kimball Way, South San Francisco, California, except for required travel by Executive on the Company's business; (v) any breach by the Company of any material provision of this Agreement; or (vi) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company. For purposes of this Agreement, "Cause" means: (V) an intentional action or intentional failure to act by Executive which was performed in bad faith and to the material detriment of the Company; (W) Executive intentionally refuses or intentionally fails to act in accordance with any lawful and proper direction or order of the Board; (X) Executive willfully and habitually neglects the duties of employment; (Y) Executive violates Section 4 or Section 5 of this Agreement or (Z) Executive is convicted of a felony crime involving moral turpitude; provided, however, that in the event that any of the foregoing events under clauses (V), (W), (X) or (Y) above is capable of being cured, the Company shall provide written notice to Executive describing the nature of such event and Executive shall thereafter have ten (10) business days to cure such event.
(c) In the event of Executive's termination upon a Change of Control, upon execution of an effective release in the form attached hereto as Exhibit A: (i) Executive shall, within seven (7) days of such termination, one lump sum payment equivalent to eighteen (18) months of his then Base Salary, plus a pro rata share of his Target Bonus for the calendar year in which such termination occurs, plus the amount of eighteen months of his Target Bonus, minus standard withholdings and deductions; (ii) all of Executive's outstanding Stock Options shall become fully vested and exercisable immediately upon the occurrence of such termination; and (iii) for a period of eighteen (18) months (or until comparable benefits coverage becomes available to Executive, if sooner), the Company shall pay the costs associated with the continuation of Executive's medical dental, and vision benefits under COBRA as in effect immediately prior to Executive's termination of employment. For purposes of this paragraph, both Executive's "Base Salary" and "Target Bonus" shall be the greater of those amounts in effect either immediately prior to the Change of Control or the termination of Executive's employment.
(d) A termination upon a Change of Control shall be deemed to occur for purposes of this Agreement in the event of a Change of Control (as defined below) upon which or within thirteen (13) months following the consummation of which: Executive does not continue to render services as President and Chief Executive Officer of the Company (or any successor or surviving corporation) or Executive terminates employment with the Company (or a successor or surviving corporation) for Good Reason. For purposes of this Agreement, a Change of Control means (i) any sale, merger, consolidation, tender offer or similar acquisition of shares, or other transaction or series of related transactions (each a "Transaction") as a result of which at least a majority of the voting power of the Company is not held, directly or indirectly, by the persons or entities who held the Company's securities with voting power before such Transaction (provided, however, that any person who acquired voting securities of the Company in contemplation of the Transaction and who immediately after such Transaction possesses direct or indirect ownership of at least ten percent (10%) of the securities of the Company or the surviving entity (or if the Company or the surviving entity is a controlled affiliate of another entity, then of such controlling entity) shall not be included in the group of those persons or entities who held the Company's securities with voting power before such Transaction); (ii) a sale or other disposition of all or a substantial part of the Company's assets, whether in one transaction or a series of related transactions; or (iii) individuals who on the date hereof constitute the Board and any new director (other than a director designated by a person or entity who has entered into an agreement to effect a transaction described in clause (i) or (ii) above) whose nomination and/or election to the Board was approved by a vote of at least a majority of the directors then still in office who either were directors on the date hereof or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority of the Board.
2.3 Golden Parachute Taxes. Notwithstanding anything contained in this Agreement to the contrary, to the extent that payments and benefits provided under this Agreement to Executive and benefits provided to, or for the benefit of, Executive under any other Company plan or agreement (such payments or benefits are collectively referred to as the "Payments") would be subject to the excise tax (the "Excise Tax") imposed under Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), the Payments shall be reduced (but not below zero) to the extent necessary so that no Payment to be made or benefit to be provided to the Executive shall be subject to the Excise Tax, but only if, by reason of such reduction, the net after-tax benefit received by Executive shall exceed the net after-tax benefit received by him if no such reduction was made. For purposes of this Section 2.3, "net after-tax benefit" shall mean (a) the Payments which Executive receives or is then entitled to receive from the Company that would constitute "parachute payments" within the meaning of Section 280G of the Code, less (b) the amount of all federal, state and local income taxes payable with respect to the foregoing calculated at the maximum marginal income tax rate for each year in which the foregoing shall be paid Executive (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (c) the amount of excise taxes imposed with respect to the payments and benefits described in (a) above by Section 4999 of the Code. The foregoing determination will be made by the a nationally recognized accounting firm (the "Accounting Firm") selected by the Company (which may be, but will not be required to be, the Company's independent auditors). The Company will direct the Accounting Firm to submit its determination and detailed supporting calculations to both the Executive and the Company within fifteen (15) days after his date of termination of employment. If the Accounting Firm determines that such reduction is required by this Section 2.3, the Executive, in his sole and absolute discretion, may determine which Payments shall be reduced to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code, and the Company shall pay such reduced amount to him. The fees and expenses of the Accounting Firm for its services in connection with the determinations and calculations contemplated by this Section 2.3 will be borne by the Company.
2.4 Annual Bonus. Executive will be eligible for an annual bonus up to fifty percent (50%) of Executive's then current Base Salary upon achievement of reasonable goals specified by the Board (the "Target Bonus"). Such goals shall be set forth in writing by the Board prior to the close of the first quarter of each fiscal year of the Company, with fifty percent (50%) of such goals to be dependent on Executive's individual performance and fifty percent (50%) of such goals to be dependent on the Company's performance.
2.5 Employee Loan. On the Effective Date, the Company agrees to loan Executive $300,000 pursuant to the terms of the form of promissory note attached hereto as Exhibit B (the "Note"). The Note is full-recourse, secured by any shares of the Company's common stock acquired by Executive upon the exercise of any Stock Options, bears interest at the rate of 5.61% per annum and is payable in full on the earlier of (a) thirty (30) days following Executive's termination of employment (other than Executive's termination of employment for Good Reason or Executive's termination of employment without Cause or due to death or disability) or (b) January 2, 2004. Provided that Executive continues to render services to the Company through each such date, the Company will forgive one thirty-sixth (1/36th) of the principal amount of the Note and any accrued interest thereon on the first day of each calendar month following the Effective Date, such that (provided Executive has not ceased to render services to the Company as of each such date) the Note shall be forgiven in its entirety on January 1, 2004. In the event Executive is terminated without Cause or due to death or disability or that Executive terminates his employment for Good Reason, the Company will concurrently therewith forgive all remaining principal and interest due under the Note.
2.6 Medical and Dental Coverage. The Company shall provide Executive with the medical and dental coverage which is no less favorable than that provided to any other executive of the Company.
2.7 Standard Company Benefits. Executive shall be entitled to all other rights and benefits for which he is eligible under the terms and conditions of such benefits which may be in effect from time to time and provided by the Company to its employees generally and/or to its management and executive employees in particular.
2.8 Expenses. Executive shall be entitled to receive prompt reimbursement of all reasonable expenses incurred by Executive in performing Company services. Executive agrees to furnish the Company reasonably adequate records and other documentary evidence of such expenses for which Executive seeks reimbursement. Such expenses shall be accounted for under the policies and procedures established by the Company.
2.9 Vacation and Sick Leave. Executive shall be entitled to vacation and to sick leave in accordance with policies as periodically established by the Company for Company officers. In addition, Executive shall be entitled, without loss of pay, to be absent voluntarily from the performance of employment duties for such periods of time and for such valid and legitimate reasons as the Board in its discretion may determine.
2.10 Stock Options.
Executive shall be granted options to purchase 500,000 shares of the Company's common stock (the "Time Vesting Options") at an exercise price equal to the fair market value of the Company's common stock as of the date of grant of such options. Provided Executive remains in continuous service with the Company as of the applicable vesting dates, twelve and one half percent (12-1/2%) of the Time Vesting Options shall vest upon the six (6) month anniversary of the Effective Date and the remaining Time Vesting Options shall vest at the rate of 1/42nd of such remaining options per month, such that one hundred percent (100%) of the Time Vesting Options shall be vested on the fourth (4th) anniversary of the Effective Date. The Time Vesting Options shall be treated as incentive stock options within the meaning of Section 422 of the Code to the maximum extent possible and shall become exercisable as they become vested, and the remaining portion of the Time Vesting Options shall become exercisable upon the date of grant of such options. The vested portion of all Stock Options which are not incentive stock options shall be transferable to family members to the maximum extent permitted by the Securities Act of 1933, as amended. Other terms and conditions of the Time Vesting Options shall be consistent with the terms of the Company's compensatory stock plan under which they are granted and as mutually agreed to by the Company and Executive. In addition to the Time Vesting Options, effective as of the Effective Date, Executive shall be granted non-statutory stock options to purchase 100,000 shares of the Company's common stock (the "Performance Vesting Options") at an exercise price equal to the fair market value of the Company's common stock as of the Effective Date. Provided Executive remains in continuous service with the Company through the seventh (7th) anniversary of the Effective Date, the Performance Vesting Options shall become vested and exercisable in their entirety as of the seventh (7th) anniversary of the Effective Date; provided however, that upon the determination by the Board of Directors that Executive has met by Executive's performance during 2001 at least seventy-five percent (75%) of certain performance goals to be established jointly by Executive and the Board and/or the Compensation Committee of the Board during the first quarter of calendar year 2001, the Performance Vesting Options shall vest and become exercisable pursuant to the schedule described above with respect to the Time Vesting Options as if governed by such schedule as of their date of grant. Other terms and conditions of the Performance Vesting Options shall be consistent with the terms of the Company's compensatory stock plan under which they are granted and as mutually agreed to by the Company and Executive. The Time Vesting Options and Performance Vesting Options, together with any additional options to purchase shares of the Company's common stock that Executive may be granted from time to time are referred to herein collectively as the "Stock Options." The Stock Options shall be granted by the Board or authorized committee of the Board, and shall be granted pursuant to, and except as provided herein shall be governed by, the terms of the Company's stock option plans and customary forms of stock option agreement as amended from time to time.3. Confidential Information Obligations.
3.1 Agreement. Executive agrees to execute and abide by Executive's Employment, Confidential Information and Invention Assignment Agreement ("Confidentiality Agreement"),
3.2 Remedies. Executive's duties under the Confidentiality Agreement shall survive termination of his employment with the Company. Executive acknowledges that a remedy at law for any breach or threatened breach by him of the provisions of the Confidentiality Agreement would be inadequate, and he therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach.
4. Outside Activities.
4.1 Except with the prior written consent of the Board, Executive will not during the term of this Agreement undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and not-for-profit activities and may, upon notice to the Board, serve as a member of Boards of Directors of companies not deemed to be engaged in competition with the Company so long as such activities do not materially interfere with the performance of his duties hereunder, and the Company hereby agrees that Executive may serve as a director of RxMarketplace.com, ViaCell, and LXR without further notice to the Board.
4.2 Except as permitted by Section 4.3, Executive agrees not to acquire, assume, or participate in (directly or indirectly) any position, investment or interest known by him to be adverse or antagonistic to the Company, its business, or its prospects, financial or otherwise.
4.3 During the term of his employment by the Company, except on behalf of the Company, Executive will not have any direct or indirect business connection or interest, in any capacity whatsoever, with any other person or entity known by him to compete directly with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company. Nothing in this paragraph shall bar Executive from owning securities of any competitor corporation as a passive investor, so long as his aggregate direct holdings in any one such corporation shall not constitute more than 1% of the voting stock of that corporation.
5. Noninterference. While employed by the Company, and for one (1) year immediately following the termination of Executive's employment, Executive agrees not to interfere with the Company's business by soliciting, attempting to solicit, inducing, or otherwise causing any employee of the Company to terminate his or her employment in order to become an employee, consultant, or independent contractor to or for any competitor of the Company. Executive agrees that this restriction is reasonably necessary to protect the Company's legitimate business interest in its substantial relationships with employees, consultants, and independent contractors and its valuable confidential business information.
6. General Provisions.
6.1 Notices. Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of (i) personal delivery (including delivery by fax or overnight courier) or (ii) the third day after mailing by first-class mail, to the Company at its primary office location and to Executive at his address as then listed in the Company's payroll records.
6.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed and construed in such jurisdiction so as to render it enforceable under applicable law insofar as possible consistent with the intent of the parties.
6.3 Waiver. If either party should waive any breach of any provisions of this Agreement, that party shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.
6.4 Complete Agreement. This Agreement and its Exhibits constitute the entire agreement between Executive and the Company and it is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes all prior letter agreements and understandings between the parties. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by both the Executive and at least one member of the Compensation Committee of the Board.
6.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.
6.6 Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
6.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any duties hereunder and may not assign any rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.
6.8 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California, without regard to such state's conflict-of- laws rules.
6.9 Non-Publication. The parties mutually agree not to disclose publicly the terms of this Agreement except to the extent that disclosure is mandated by applicable law or such disclosure is to the parties' respective attorneys, accountants other advisors, and immediate family.
6.10 Agreement Controls. In the event of a conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control.
6.11 Attorneys' Fees. If either party hereto brings any action to enforce his or its rights hereunder, each party in any such action shall be responsible for his or its costs and attorneys fees incurred in connection with such action.
6.12 Tax Withholding. All payments made pursuant to this Agreement shall be subject to all applicable federal, state and local income and employment tax withholding.
6.13 Arbitration. To ensure rapid and economical resolution of any and all disputes which may arise under this Agreement, the Company and Executive each agree that any and all disputes or controversies, whether of law or fact of any nature whatsoever (including, but not limited to, all state and federal statutory and common law discrimination claims), with the sole exception of those disputes which may arise from Executive's Confidentiality Agreement, arising from or regarding the interpretation, performance, enforcement or breach of this Agreement, or any other disputes or claims arising from or related to Executive's employment or the termination of his employment, shall be resolved by final and binding confidential arbitration conducted by Judicial Arbitration and Mediation Services Inc. ("JAMS") under the then existing JAMS Rules of Practice and Procedure; provided that the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator's essential findings and conclusions and a statement of the award. The Company shall pay all of Executives' JAMS arbitration fees. In addition to any other relief, the arbitrator may award to the prevailing party recovery of its attorneys' fees and costs. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.
6.14 Right to Work. As required by law, this offer of employment is subject to satisfactory proof of Executive's right to work in the United States.
6.15 No Duty to Seek Employment. Executive and the Company acknowledge and agree that nothing contained in the Agreement shall be construed as requiring Executive to seek or accept alternative or replacement employment in the event of his termination of employment by the Company for any reason, and no payment or benefit payable hereunder shall be conditioned on Executive's seeking or accepting such alternative or replacement employment.
[Remainder of this page intentionally left blank]
In Witness Whereof, the parties have executed this Agreement on the day and year first above written.
Axys Pharmaceuticals, Inc.
By: /s/ Douglas Altschuler
Name: Douglas Altschuler
Title: V.P./General Counselor
Accepted and agreed this
23rd day of January, 2001
/s/ Paul J. Hastings
Paul Hastings
Exhibit A
RELEASE
Certain capitalized terms used in this Release are defined in the Employment Agreement entered into as of _____________, 2000 between Axys Pharmaceuticals, Inc. and me which I have reviewed.
I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: "A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company.
Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to claims and demands directly or indirectly arising out of my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims or demands related to salary, bonuses, commissions, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of disputed compensation; claims pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended ("ADEA"); the federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful discharge; discrimination; fraud; defamation; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from its obligation to indemnify me from any third party action brought against me based on my employment with the Company, pursuant to the Company's by-laws, any applicable agreement or applicable law, or to reduce or eliminate any coverage I may have under the Company's director and officer liability policy, if any.
I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this Release; (B) I should consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following the execution of this Release to revoke this Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day after this Release is executed by me.
Paul Hastings
Date:____________________
Exhibit 10.153
AXYS PHARMACEUTICALS, INC.
PLEDGE AGREEMENT
THIS PLEDGE AGREEMENT is made and entered into as of __________ ___, 2000 by Paul Hastings (the "Pledgor"), in favor of Axys Pharmaceuticals, Inc. (the "Secured Party").
RECITALS
AGREEMENT
NOW, THEREFORE, in consideration of the premises and in order to induce the Secured Party to advance funds to the Pledgor, the Pledgor hereby agrees with the Secured Party and grants as follows:
(i) The Pledgor shall be entitled to exercise any and all voting and other consensual rights pertaining to the Pledged Collateral or any part thereof for any purpose not inconsistent with the terms of this Pledge Agreement or the Promissory Note; provided, however, that the Pledgor shall not exercise or refrain from exercising any such right if, in the Secured Party's judgment, such action or inaction would have a material adverse effect on the value of the Pledged Collateral or any part thereof; and provided, further, that the Pledgor shall give the Secured Party at least thirty (30) days' written notice of the manner in which he intends to exercise, and the reasons therefor, or the reasons for refraining from exercising, any such right.
(ii) The Pledgor shall be entitled to receive all cash dividends and other cash distributions paid or payable with respect to any of the Pledged Collateral. Any and all instruments and other property (other than cash or checks) received, receivable or otherwise distributed in respect of, or in exchange for, any Pledged Collateral, shall be, and shall be forthwith delivered to the Secured Party to hold as Pledged Collateral and shall, if received by the Pledgor, be received in trust for the benefit of the Secured Party, be segregated from the other property or funds of Pledgor, and be forthwith delivered to the Secured Party as Pledged Collateral in the same form as so received (with any necessary indorsement).
(i) All rights of the Pledgor to exercise the voting and other consensual rights which he would otherwise be entitled to exercise pursuant to Section 6(a)(i) and to receive the dividends which he would otherwise be authorized to receive and retain pursuant to Section 6(a)(ii) shall cease, and all such rights shall, upon notice by the Secured Party to the Pledgor, become vested in the Secured Party who shall thereupon have the sole right to exercise such voting and other consensual rights and the sole right to receive and hold as Pledged Collateral such dividends (and to the extent permissible, apply them to the Obligations of Pledgor).
(ii) All dividends which are received by the Pledgor contrary to the provisions of paragraph (i) of this Section 6(b) shall be received in trust for the benefit of the Secured Party, shall be segregated from other funds of the Pledgor and shall be forthwith paid over to the Secured Party as Pledged Collateral in the same form as so received (with any necessary indorsement).
IN WITNESS WHEREOF, the parties hereto have caused this Pledge Agreement to be duly executed and delivered as of the date first above written.
Pledgor:
Paul Hastings
Secured Party:
AXYS PHARMACEUTICALS, INC.
By:________________________________
EXHIBIT A
(1) Options
to purchase 500,000 shares of the Company's common stock (the "Time Vesting Options") as described in Section 2.10 of that certain Employment Agreement dated as of ______________, 2000 between the Company and Pledgor (the "Employment Agreement").(2)
Options to purchase an additional 100,000 shares of the Company's common stock (the "Performance Vesting Options") as described in Section 2.10 of the Employment Agreement.Exhibit 10.154
Exhibit B
PROMISSORY NOTE
$300,000 South San Francisco, California
January 2, 2000
For Value Received, the undersigned hereby unconditionally, promises to pay to the order of Axys Pharmaceuticals, Inc., a Delaware corporation (the "Company"), at the offices of the Company, 180 Kimball Way, South San Francisco, California, or at such other place as the holder hereof may designate in writing, in lawful money of the United States of America and in immediately available funds, the principal sum of Three Hundred Thousand Dollars ($300,000) and interest accrued from the date hereof on the unpaid principal at the rate of 5.61% per annum, or the maximum rate permissible by law (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans), whichever is less, compounded annually, as follows:
Principal Repayment. The outstanding principal amount hereunder shall be due and payable in full on January 2, 2004 and
Interest Payments. Interest shall be compounded annually (calculated on the basis of a 365-day year for the actual number of days elapsed) and shall be payable in arrears on the Principal Repayment Date.
In addition, and notwithstanding the foregoing, provided that the undersigned continues to render services to the Company through each such date, the Company will forgive one thirty-sixth (1/36th) of the principal amount of the Note and any accrued interest thereon on the first day of each calendar month following the date hereof. In the event the undersigned ceases providing services to the Company, whether as an employee, consultant, or member of the Company's Board of Directors, for any reason or no reason, the principal and all accrued interest due under this Note shall become due and payable in full no later than thirty (30) days after the date of such final cessation of service (but in no event later than the Principal Repayment Date); provided, however, that in the event the undersigned is terminated without Cause or due to death or disability or that the undersigned terminates his employment for Good Reason, the Company will concurrently therewith forgive all remaining principal and interest due under the Note. Capitalized terms used herein without definition shall be defined to have the same meaning as such terms have in that certain Employment Agreement dated as of January 2, 2001 between the Company and the undersigned.
This Note may be prepaid at any time without penalty. All money paid toward the satisfaction of this Note shall be applied first to the payment of interest as required hereunder and then to the retirement of the principal.
The full amount of this Note is secured by a pledge of any shares of Common Stock of the Company that the undersigned may purchase from time to time through the exercise of Company stock options, and is subject to all of the terms and provisions of that form of Pledge Agreement between the undersigned and the Company, attached as Exhibit A.
The undersigned hereby represents and agrees that the amount due under this Note are not consumer debt, and are not incurred primarily for personal, family or household purposes, but are for business and commercial purposes only.
The undersigned hereby waives presentment, protest and notice of protest, demand for payment, notice of dishonor and all other notices or demands in connection with the delivery, acceptance, performance, default or endorsement of this Note.
The holder hereof shall be entitled to recover, and the undersigned agrees to pay when incurred all costs and expenses of collection of this Note, including without limitation, reasonable attorneys' fees.
This Note shall be governed by, and construed, enforced and interpreted in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.
Signed ____________________________
Paul Hastings